-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GI-301 in Allergic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GI-301 in Allergic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Allergic Asthma Drug Details: GI-301 is under development for chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GI-301 in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GI-301 in Chronic Urticaria Or Hives report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Chronic Urticaria Or Hives Drug Details: GI-301 is...
-
Company Insights
Innovation and Patenting activity of General Interface Solution (GIS) Holding Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of General Interface Solution (GIS) Holding Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Sector Analysis
NewKyrgyzstan Insurance Industry – Key Trends and Opportunities to 2028
Kyrgyzstan Insurance Market Report Overview The gross written premium of the Kyrgyzstan insurance market was KGS3 billion ($34.7 million) in 2023. The market will achieve a CAGR of more than 12% during 2024-2028. The Kyrgyzstan insurance market research report provides in-depth market analysis, information, and insights into the Kyrgyzstan insurance industry. It provides a detailed outlook by product category as well as values for key performance indicators such as gross written premium, penetration, premium accepted and ceded, profitability ratios, and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GI-301 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GI-301 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Atopic Dermatitis (Atopic Eczema) Drug Details: GI-301 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Everolimus in Papillary Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in Papillary Thyroid Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Papillary Thyroid Cancer Drug Details: Everolimus (Afinitor, Votubia, RAD001)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Everolimus in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Metastatic Transitional (Urothelial) Tract Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Everolimus in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in High-Grade Glioma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in Low-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Low-Grade Glioma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Everolimus in Medullary Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in Medullary Thyroid Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Medullary Thyroid Cancer Drug Details: Everolimus (Afinitor, Votubia, RAD001)...